Close Menu

NEW YORK — Sera Prognostics is collaborating with insurer Anthem and its subsidiary HealthCore on a study investigating Sera's PreTRM test for preterm birth risk as the company works to build evidence of its effectiveness that it hopes will drive insurer coverage.

The study's goal is to determine whether the PreTRM test can improve patient outcomes and reduce healthcare spending when used with various Anthem plans.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.